Angiostatin, formed by gelatinase B/MMP-9 digestion of plasminogen and plasmin [112,113], acts as a competitive inhibitor of tissue-type plasminogen activator and single chain urokinase-mediated plasminogen activation, inhibits plasmin-mediated laminin degradation, impairs plasminogen association with the tumour cell surface, and inhibits plasmin-dependent tumour invasion and angiogenesis [113,285]. The gene discussed is PLG; the disease is neoplasm.